Details of the Drug

General Information of Drug (ID: DM0GXWT)

Drug Name
ABP 654
Synonyms Ustekinumab biosimilar
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 3 [1]
Psoriatic arthritis FA21 Phase 3 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DVT8O0
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [2]
Interleukine 12 (IL-12) TTG68FB IL12A_HUMAN ; IL12B_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Amgen